Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study

Interventions

• Drug
  Methotrexate

  Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.

• Drug
  pralatraxate,

  Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

• Drug
  Ifosfamide

  Patients will receive Ifsofamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

• Drug
  Dexamethasone

  Patients will receive dexamethasone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

• Drug
  Etoposide

  Patients will receive etoposide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

• Drug
  calaspargase pegol

  Patients will receive pegaspargase as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

• Drug
  cyclophosphamide

  Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

• Drug
  Doxorubicin

  Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

• Drug
  Prednisone

  Patients will receive prednisone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

• Drug
  Brentuximab Vedotin

  Patients will receive brentuximab vedotin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

Locations (6)